Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Ablynx
Ablynx, Procter & Gamble extend Nanobody agreement
May 8th, 2006
Ablynx, a developer of Nanobodies, has announced that its drug discovery and development alliance with Procter & Gamble Pharmaceuticals, Inc., (P&GP), a subsidiary of The Procter & Gamble Company (PG) has been extended to include metabolic disease targets. Through this agreement, Ablynx will use its unique and patent protected Nanobody platform to discover and develop drug candidates against targets specified by P&GP. Under terms of the agreement, P&GP provides Ablynx with research and development funding, milestone payments, and royalties upon commercialization. Ablynx is responsible for discovering Nanobodies that meet an agreed product profile....
Source: Biotech Week (2006-05-08)
|
